A Study of Single Dose of LP-003 in Healthy Adult Subjects
Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Longbio Pharma
Collaborator:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine